Ashland Inc.
NYSE•ASH
CEO: Mr. Guillermo Novo
板块: Basic Materials
行业: Chemicals - Specialty
上市日期: 1980-03-17
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives. Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
联系方式
市值
$2.63B
市盈率 (TTM)
-3.8
28.9
股息率
2.9%
52周最高
$65.65
52周最低
$45.21
52周范围
排名42Top 47.5%
3.9
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 3.9 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q1 2026 数据
营业收入
$386.00M-4.69%
近4季度走势
每股收益
-$0.26-92.57%
近4季度走势
自由现金流
$111.00M-276.19%
近4季度走势
2026 Q1 财报亮点
核心亮点
Net Loss Significantly Narrows Net loss reduced to $(12)M for the quarter, a $153M improvement versus prior year period results.
Operating Cash Flow Strong Cash provided by operating activities from continuing operations reached $125M, up from $(30)M outflow last year.
Adjusted EBITDA Slight Dip Adjusted EBITDA was $58M, slightly down $3M from $61M, driven by portfolio optimization impacts.
Divestiture Impact on Sales Total sales were $386M, down $19M, reflecting an $11M volume drop and $10M impact from Avoca business sale.
关注风险
Credit Rating Downgrade Risk Moody's Investor Services downgraded corporate credit rating to Ba2 during the quarter, potentially affecting future borrowing costs.
Lower Volume Pressures Sales Total sales decreased $19M, driven by lower volume and unfavorable pricing, partially offset by favorable foreign currency exchange.
Trade Policy Geopolitical Uncertainty Continuing regulatory activity regarding tariffs and global trade disputes creates macroeconomic and geopolitical uncertainty risks.
Asbestos Litigation Reserves Large Total reserves for Ashland's asbestos claims stood at $246M at period end, subject to future estimation changes.
前瞻展望
FY2026 Adjusted EBITDA Narrowed Full year fiscal 2026 Adjusted EBITDA guidance narrowed to $400M to $420M range, reflecting temporary impacts.
Optimization Program Cost Savings Manufacturing optimization program on track, expecting $30M cost savings under the $90M program for fiscal 2026.
Core Markets Remain Resilient Personal Care and Life Sciences core end markets expected to remain resilient, supported by stable fundamentals and innovation traction.
Share Repurchase Availability High $520 million remained available for repurchase under the $1B evergreen stock repurchase program as of December 31, 2025.
同行对比
营业收入 (TTM)
$7.96B
$5.81B
$3.56B
毛利率 (最新季度)
56.2%
34.4%
32.3%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| MEOH | $4.41B | 20.6 | 9.0% | 48.0% |
| SKE | $4.03B | -45.3 | -109.2% | 9.5% |
| AVNT | $3.58B | 43.7 | 3.5% | 31.9% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
-6.9%
增长承压
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
100%
现金流表现优异
深度研究
下次财报:2026年4月28日
每股收益:-
|营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据